Anti-VEGF agents and glaucoma filtering surgery

Journal of Ophthalmic and Vision Research

Volumn 8, Issue 2, 2013, Pages 182-186

  Daneshvar, Ramin ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880077447     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-346.
2. Skuta GL, Parrish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987;32:149-170.
3. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K 1983;103:84-88.
4. Crowston JG. Long-term outcomes of trabeculectomy. Clin Experiment Ophthalmol 2008;36:705-706.
5. Sihota R, Sharma T, Agarwal HC. Intraoperative mitomycin C and the corneal endothelium. Acta Ophthalmol Scand 1998;76:80-82.
6. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992;114:544-553.
7. Watson PG, Jakeman C, Ozturk M, Barnett MF, Barnett F, Khaw KT. The complications of trabeculectomy (a 20-year follow-up). Eye (Lond) 1990;4:425-438.
8. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008;88:579-590.
9. Li Z, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009;50:5217-5225.
10. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-H576.
11. Zachary I. VEGF signalling: integration and multitasking in endothelial cell biology. Biochem Soc Trans 2003;31:1171-1177.
12. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouché A, Yuce A, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 2002;109:327-336.
13. Zhang Y, Furumura M, Morita E. Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. Growth Factors 2008;26:125-131.
14. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006;10:515-527.
15. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000;83:63-68.
16. Van Bergen T, Vandewalle E, Van de Veire S, Dewerchin M, Stassen JM, Moons L, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 2011;93:689-699.
17. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009;62:707-709.
18. August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 2008;97:180-185.
19. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma 2002;11:406-410.
20. Lopilly Park HY, Kim JH, Ahn MD, Park CK. Level of vascular endothelial growth factor in tenon tissue and results of glaucoma surgery. Arch Ophthalmol 2012;130:685-689.
21. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008;115:2141-2145.
22. Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (Lond) 2009;23:979-981.
23. de Moraes CG, Facio AC, Costa JH, Malta RF. Intracameral bevacizumab and mitomycin C trabeculectomy for eyes with neovascular glaucoma: a case series. J Ocul Biol Dis Infor 2009;2:40-46.
24. Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma 2010;19:622-626.
25. Choi JY, Choi J, Kim YD. Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: a case series. Korean J Ophthalmol 2010;24:47-52.
26. Fakhraie G, Katz LJ, Prasad A, Eslami Y, Sabour S, Zarei R, et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma. J Glaucoma 2010;19:212-218.
27. Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 2010;88:96-102.
28. Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Acta Ophthalmol 2011;5:841-845.
29. Miki A, Oshima Y, Otori Y, Matsushita K, Nishida K. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy. Eye (Lond) 2011;25:658-659.
30. Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthalmol 2011;5:797-800.
31. Takihara Y, Inatani M, Kawaji T, Fukushima M, Iwao K, Iwao M, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 2011;20:196-201.
32. Jurkowska-Dudzinska J, Kosior-Jarecka E, Zarnowski T. Comparison of the use of 5-fluorouracil and bevacizumab in primary trabeculectomy: results at 1 year. Clin Experiment Ophthalmol 2012;40:e135-e142.
33. Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 2012;153:352-357.
34. Sengupta S, Venkatesh R, Ravindran RD. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma 2012;21:450-459.
35. Akkan JU, Cilsim S. Role of subconjunctival bevacizumab as an adjuvant to primary trabeculectomy: a prospective randomized comparative 1-year follow-up study. J Glaucoma 2013; May 8 [Epub ahead of print].
36. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010;150:399-403.
37. Elmekawey H, Khafagy A. Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma. J Glaucoma 2013; Apr 29 [Epub ahead of print].
38. Zarnowski T, Tulidowicz-Bielak M. Topical bevacizumab is efficacious in the early bleb failure after trabeculectomy. Acta Ophthalmol 2011;89:e605-e606.
39. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-4813.
40. Azuara-Blanco A, Bond JB, Wilson RP, Moster MR, Schmidt CM. Encapsulated filtering blebs after trabeculectomy with mitomycin-C. Ophthalmic Surg Lasers 1997;28:805-809.
41. Katz GJ, Higginbotham EJ, Lichter PR, Skuta GL, Musch DC, Bergstrom TJ, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995;102:1263-1269.
42. Campagna JA, Munden PM, Alward WL. Tenon's cyst formation after trabeculectomy with mitomycin C. Ophthalmic Surg 1995;26:57-60.
43. Georgalas I, Papaconstantinou D, Tservakis I, Koutsandrea C, Ladas I. Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab. Ther Clin Risk Manag 2009;5:17-19.